Stock Notes

Dr Reddy's Laboratories

Every Finvezto stock note on Dr Reddy's Laboratories, dated and newest first. Coverage spans pharma / oncology.

1 note and counting
13 Jun 2026
Dr Reddy's Laboratories launched the first-to-market generic of Pfizer's Bosulif, bosutinib 400 mg, in the United States with 180 days of exclusivity.
The brand drew about 254 million dollars in US sales in the year to April 2026, and exclusivity caps competition while margins stay rich.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.